Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer

PURPOSE: Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical manageme...

Descripción completa

Detalles Bibliográficos
Autores principales: Behel, Vichitra, Noronha, Vanita, Choughule, Anuradha, Shetty, Omshree, Chandrani, Pratik, Kapoor, Akhil, Bondili, Suresh Kumar, Bajpai, Jyoti, Kumar, Rajiv, Pai, Trupti, Bal, Munita, Gurav, Mamta, Bapat, Prachi, Mittal, Neha, Menon, Santosh, Patil, Vijay, Menon, Nandini, Dutt, Amit, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296182/
https://www.ncbi.nlm.nih.gov/pubmed/35802838
http://dx.doi.org/10.1200/GO.22.00030
_version_ 1784750215008354304
author Behel, Vichitra
Noronha, Vanita
Choughule, Anuradha
Shetty, Omshree
Chandrani, Pratik
Kapoor, Akhil
Bondili, Suresh Kumar
Bajpai, Jyoti
Kumar, Rajiv
Pai, Trupti
Bal, Munita
Gurav, Mamta
Bapat, Prachi
Mittal, Neha
Menon, Santosh
Patil, Vijay
Menon, Nandini
Dutt, Amit
Prabhash, Kumar
author_facet Behel, Vichitra
Noronha, Vanita
Choughule, Anuradha
Shetty, Omshree
Chandrani, Pratik
Kapoor, Akhil
Bondili, Suresh Kumar
Bajpai, Jyoti
Kumar, Rajiv
Pai, Trupti
Bal, Munita
Gurav, Mamta
Bapat, Prachi
Mittal, Neha
Menon, Santosh
Patil, Vijay
Menon, Nandini
Dutt, Amit
Prabhash, Kumar
author_sort Behel, Vichitra
collection PubMed
description PURPOSE: Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical management of patients with cancer. METHODS: This study was conducted at a tertiary cancer center in India. Cases to be discussed in the MTB were identified by molecular pathologists, scientists, or oncologists. On the basis of the clinical data and molecular test reports, a course of clinical management was recommended and made available to the treating oncologist. We determined the proportion of patients who were recommended a change in the clinical management. We also assessed compliance of the treating oncologists with MTB recommendations. RESULTS: There were 339 discussions for 328 unique patients. The median age of the cohort was 54 years (range 17-87), and the majority of the patients were men (65.1%). Of 339 cases, 133 (39.2%) were recommended continuation of ongoing therapy while the remaining 206 (60.7%) were recommended a change in clinical management. Compliance with MTB recommendations for a change in clinical management was 58.5% (79 of 138 evaluable cases). Compliance and implementation for MTB's recommendation to start a new therapy in 104 evaluable cases were 60.5% and 44.2%, respectively. A total of 248 biopsies had at least one actionable mutation. A total of 646 mutations were identified in the cohort, with EGFR being the most frequently altered gene. CONCLUSION: MTBs help in interpreting results of molecular tests, understanding the significance of molecular abnormalities, and assessing the benefits of available targeted therapies and clinical trials in the management of patients with targetable genetic alterations.
format Online
Article
Text
id pubmed-9296182
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-92961822022-08-01 Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer Behel, Vichitra Noronha, Vanita Choughule, Anuradha Shetty, Omshree Chandrani, Pratik Kapoor, Akhil Bondili, Suresh Kumar Bajpai, Jyoti Kumar, Rajiv Pai, Trupti Bal, Munita Gurav, Mamta Bapat, Prachi Mittal, Neha Menon, Santosh Patil, Vijay Menon, Nandini Dutt, Amit Prabhash, Kumar JCO Glob Oncol ORIGINAL REPORTS PURPOSE: Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical management of patients with cancer. METHODS: This study was conducted at a tertiary cancer center in India. Cases to be discussed in the MTB were identified by molecular pathologists, scientists, or oncologists. On the basis of the clinical data and molecular test reports, a course of clinical management was recommended and made available to the treating oncologist. We determined the proportion of patients who were recommended a change in the clinical management. We also assessed compliance of the treating oncologists with MTB recommendations. RESULTS: There were 339 discussions for 328 unique patients. The median age of the cohort was 54 years (range 17-87), and the majority of the patients were men (65.1%). Of 339 cases, 133 (39.2%) were recommended continuation of ongoing therapy while the remaining 206 (60.7%) were recommended a change in clinical management. Compliance with MTB recommendations for a change in clinical management was 58.5% (79 of 138 evaluable cases). Compliance and implementation for MTB's recommendation to start a new therapy in 104 evaluable cases were 60.5% and 44.2%, respectively. A total of 248 biopsies had at least one actionable mutation. A total of 646 mutations were identified in the cohort, with EGFR being the most frequently altered gene. CONCLUSION: MTBs help in interpreting results of molecular tests, understanding the significance of molecular abnormalities, and assessing the benefits of available targeted therapies and clinical trials in the management of patients with targetable genetic alterations. Wolters Kluwer Health 2022-07-08 /pmc/articles/PMC9296182/ /pubmed/35802838 http://dx.doi.org/10.1200/GO.22.00030 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Behel, Vichitra
Noronha, Vanita
Choughule, Anuradha
Shetty, Omshree
Chandrani, Pratik
Kapoor, Akhil
Bondili, Suresh Kumar
Bajpai, Jyoti
Kumar, Rajiv
Pai, Trupti
Bal, Munita
Gurav, Mamta
Bapat, Prachi
Mittal, Neha
Menon, Santosh
Patil, Vijay
Menon, Nandini
Dutt, Amit
Prabhash, Kumar
Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
title Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
title_full Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
title_fullStr Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
title_full_unstemmed Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
title_short Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
title_sort impact of molecular tumor board on the clinical management of patients with cancer
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296182/
https://www.ncbi.nlm.nih.gov/pubmed/35802838
http://dx.doi.org/10.1200/GO.22.00030
work_keys_str_mv AT behelvichitra impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT noronhavanita impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT choughuleanuradha impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT shettyomshree impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT chandranipratik impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT kapoorakhil impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT bondilisureshkumar impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT bajpaijyoti impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT kumarrajiv impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT paitrupti impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT balmunita impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT guravmamta impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT bapatprachi impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT mittalneha impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT menonsantosh impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT patilvijay impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT menonnandini impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT duttamit impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer
AT prabhashkumar impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer